Results 41 to 50 of about 714 (150)

The Effect of Asfotase Alfa on Plasma and Urine Pyrophosphate Levels and Pseudofractures in a Patient With Adult-Onset Hypophosphatasia. [PDF]

open access: yesJBMR Plus, 2023
Hypophosphatasia (HPP) is an inherited disease caused by variants of the ALPL gene encoding tissue‐nonspecific alkaline phosphatase. Adult‐onset HPP (adult HPP), known as a mild form of HPP, develops symptoms involving osteomalacia after the age of 18 ...
Hidaka N   +14 more
europepmc   +2 more sources

Impact of discontinuing 5 years of enzyme replacement treatment in a cohort of 6 adults with hypophosphatasia: A case series

open access: yesBone Reports, 2022
Asfotase alfa is a human recombinant enzyme replacement therapy for hypophosphatasia. We describe 6 adults who were treated with asfotase alfa for 61–68 months in a clinical trial (NCT01163149), after which asfotase alfa was discontinued for 15–48 months.
Cheryl Rockman-Greenberg   +3 more
doaj   +1 more source

Visualization of asfotase alfa-binding to sites of calcification in vivo

open access: yesBone Reports, 2020
Flavia Amadeu de Oliveira   +3 more
doaj   +2 more sources

Hypophosphatasia: from birth to adulthood [PDF]

open access: yesArchives of Endocrinology and Metabolism, 2023
Hypophosphatasia (HPP) is an inherited disease caused by a low activity of tissue-nonspecific alkaline phosphatase, a hydrolase that removes phosphate groups from many molecules.
Fernanda Salles Reis   +1 more
doaj   +1 more source

Characterization of tracheobronchomalacia in infants with hypophosphatasia

open access: yesOrphanet Journal of Rare Diseases, 2020
Background Perinatal and infantile hypophosphatasia (HPP) are associated with respiratory failure and respiratory complications. Effective management of such complications is of key clinical importance.
Raja Padidela   +12 more
doaj   +1 more source

Pharmacodynamics of asfotase alfa in adults with pediatric-onset hypophosphatasia

open access: yesBone, 2021
Hypophosphatasia (HPP) is the rare, inherited, metabolic bone disease characterized by low activity of the tissue-nonspecific isoenzyme of alkaline phosphatase (TNSALP) leading to excess extracellular inorganic pyrophosphate (PPi) and pyridoxal 5'-phosphate (PLP). Asfotase alfa is the human recombinant enzyme-replacement therapy that replaces deficient
Lothar, Seefried   +6 more
openaire   +2 more sources

Modern Approaches to the Management of Children with Hypophosphatasia

open access: yesПедиатрическая фармакология, 2023
Hypophosphatasia is rare genetic disease caused by tissue-nonspecific alkaline phosphatase deficiency due to the mutation in the ALPL gene. Disease can manifest in utero, in childhood or in adults depending on its form and severity. This article presents
Aleksander A. Baranov   +22 more
doaj   +1 more source

Home - About - Disclaimer - Privacy